# A Study of Galcanezumab (LY2951742) in Adults With Treatment-Resistant Migraine

> **NCT03559257** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 463 (actual)

## Conditions studied

- Migraine

## Interventions

- **DRUG:** Galcanezumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03559257
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-07-31
- **Primary completion:** 2019-06-19
- **Final completion:** 2019-09-19
- **Target enrollment:** 463 (ACTUAL)
- **Last updated:** 2020-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03559257

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03559257, "A Study of Galcanezumab (LY2951742) in Adults With Treatment-Resistant Migraine". Retrieved via AI Analytics 2026-07-29 from https://api.ai-analytics.org/clinical/NCT03559257. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*